2023
DOI: 10.2147/ijgm.s408900
|View full text |Cite
|
Sign up to set email alerts
|

GBP5 Identifies Immuno-Hot Tumors and Predicts the Therapeutic Response to Immunotherapy in NSCLC

Abstract: Background Immunotherapy drugs, immune checkpoint inhibitors (ICIs), have been approved for first- and second-line treatment of non-small cell lung cancer (NSCLC), but only a portion of patients respond to ICIs. It is crucial to screen the beneficiaries of immunotherapy through biomarkers accurately. Methods Several datasets were used to explore the predictive value for immunotherapy and immune relevance of guanylate binding protein 5 (GBP5) in NSCLC, including the GSE1… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 36 publications
0
1
0
Order By: Relevance
“…This suggests to integrate PD-L1 expression with tumor immune cells infiltrate to refine onco-virotherapy selection for patients ( 43 ) ( Figure 4 , framed in pink). Indeed, PD-L1 expression and a high T-cell infiltration are part of features to define a “hot” tumor which is mostly effective to immunotherapies ( 44 ).…”
Section: Resultsmentioning
confidence: 99%
“…This suggests to integrate PD-L1 expression with tumor immune cells infiltrate to refine onco-virotherapy selection for patients ( 43 ) ( Figure 4 , framed in pink). Indeed, PD-L1 expression and a high T-cell infiltration are part of features to define a “hot” tumor which is mostly effective to immunotherapies ( 44 ).…”
Section: Resultsmentioning
confidence: 99%